ICU Medical (ICUI) Heads To Wells Fargo Conference As Fair Value Debate Builds

ICU Medical (ICUI) is on investor radar as management prepares to present at the Wells Fargo 21st Annual Healthcare Conference in Boston, scheduled for September 9 and 10, 2026.

Recent trading has been choppy for ICU Medical. The stock has fallen 11.74% on a 30-day share price return and 5.21% on a 7-day share price return. It still carries a 12.70% 90-day share price return and a 1-year total shareholder return of 20.54% from a base that leaves the 5-year total shareholder return down 33.98%. This suggests momentum has improved recently, but long-term holders are still under water as investors reassess risk ahead of events like the Wells Fargo conference.

Scan beyond ICU Medical by comparing its profile with a curated list of solid balance sheet and fundamentals (24 results) to see how other healthcare suppliers with resilient finances are positioned around key conferences and catalysts.

ICU Medical now sits between a 20.5% 1-year total return and a recent pullback that has shaken confidence. Is this the moment to step in, or does patience for a cheaper entry make more sense as valuation comes under the microscope next?

Most Popular Narrative: 15.9% Undervalued

ICU Medical's most followed valuation story pegs fair value at $191.50 per share compared with the latest close at $161.00, framing the Wells Fargo conference against a sizeable implied gap.

Manufacturing network consolidations, portfolio optimization, and realization of integration synergies from the Smiths Medical acquisition are driving visible improvements in gross margin, while further benefits are expected once remaining plant transitions complete over the next year. Sustained gross margin expansion supports higher profitability.

Read the complete narrative.

Want to see what is baked into that $191.50 figure? The narrative focuses on rising pump demand, richer margins, and a re-rated earnings base. It explores which specific growth path and profitability targets would need to align for that valuation to hold. The full breakdown shows how those moving parts connect to the current discount.

Result: Fair Value of $191.50 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the ICU Medical story can be knocked off course if regulatory scrutiny around recalls lingers, or if tariffs and integration costs continue to squeeze profitability.

Find out about the key risks to this ICU Medical narrative.

Another View on ICU Medical Valuation

The DCF story around ICU Medical points to value, yet the simple P/E lens paints a tougher picture. The shares trade on a 133.8x P/E, while both peers and the fair ratio sit at 33.7x and the wider US Medical Equipment group is at 26.3x. That gap raises a practical question for investors: Is the embedded optimism already doing too much heavy lifting before execution fully plays through?

For a closer look at how those earnings multiples stack up against what the numbers suggest the ratio could move toward, have a look at the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals around ICU Medical can leave investors torn, so move quickly to review the numbers, consider both sides, and see the 4 key rewards and 3 important warning signs

Looking for more ICU Medical investment ideas?

ICU Medical puts one healthcare story on your screen, but your next strong move probably sits in a shortlist of other opportunities waiting to be reviewed.

• Target high quality value by scanning a curated set of companies trading below what their fundamentals suggest with the 31 high quality undervalued stocks.
• Protect your downside first and hunt for resilience using a prefiltered pool of businesses on the 10 resilient stocks with low risk scores.
• Spot tomorrow's potential standouts early by working through a tight 17 high quality undiscovered gems before the crowd catches on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com